SG11201811442UA - Formulation of a peptide vaccine - Google Patents

Formulation of a peptide vaccine

Info

Publication number
SG11201811442UA
SG11201811442UA SG11201811442UA SG11201811442UA SG11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA
Authority
SG
Singapore
Prior art keywords
international
pharmaceutical composition
pct
composition
reconstitution
Prior art date
Application number
SG11201811442UA
Inventor
Gwenn Eveline Mulder
Original Assignee
Isa Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V filed Critical Isa Pharmaceuticals B V
Publication of SG11201811442UA publication Critical patent/SG11201811442UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/220463 Al 28 December 2017 (28.12.2017) WIP0 I PCT (51) International Patent Classification: A61K 39/00 (2006.01) A61K 47/12 (2006.01) A61K 39/12 (2006.01) A61K 9/107 (2006.01) A61K 9/00 (2006.01) A61K 47/44 (2017.01) A61K 47/10 (2017.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2017/064882 (22) International Filing Date: 19 June 2017 (19.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16175215.9 20 June 2016 (20.06.2016) EP (71) Applicant: ISA PHARMACEUTICALS B.V. [NL/NL]; J.H. Oortweg 19, 2333 CH Leiden (NL). (72) Inventor: MULDER, Gwenn Eveline; Draaiweg 13, 3515 EJ Utrecht (NL). Agent: NEDERLANDSCH OCTROOIBUREAU; P.O. (74) Box 29720, 2502 LS The Hague (NL). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) Published: ,- 1 — with international search report (Art. 21(3)) ..! — with sequence listing part of description (Rule 5.2(a)) M 71- 0 el (54) Title: FORMULATION OF A PEPTIDE VACCINE ei ---- (57) : The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising IN , I said reconstitution composition. The invention further relates to a method of treatment using said pharmaceutical composition and/or C::::) the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for N preparing a pharmaceutical composition using the reconstitution composition of the invention. C
SG11201811442UA 2016-06-20 2017-06-19 Formulation of a peptide vaccine SG11201811442UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16175215 2016-06-20
PCT/EP2017/064882 WO2017220463A1 (en) 2016-06-20 2017-06-19 Formulation of a peptide vaccine

Publications (1)

Publication Number Publication Date
SG11201811442UA true SG11201811442UA (en) 2019-01-30

Family

ID=56148213

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811442UA SG11201811442UA (en) 2016-06-20 2017-06-19 Formulation of a peptide vaccine

Country Status (14)

Country Link
US (3) US10702598B2 (en)
EP (2) EP3552623A1 (en)
JP (2) JP7115803B2 (en)
KR (2) KR20230030032A (en)
CN (2) CN109641039B (en)
AU (1) AU2017281389B2 (en)
CA (1) CA3027459A1 (en)
EA (1) EA201990071A1 (en)
IL (2) IL291537B2 (en)
MX (2) MX2018015749A (en)
MY (1) MY189551A (en)
SG (1) SG11201811442UA (en)
WO (1) WO2017220463A1 (en)
ZA (1) ZA202100578B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2543453A (en) 2014-06-26 2017-04-19 Univ Rockefeller Acinetobacter lysins
IL294055A (en) * 2015-03-20 2022-08-01 Childrens Nat Medical Ct Generating virus or other antigen-specific t cells from a naive t cell population
KR20200003390A (en) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 Alpha virus neoantigen vector
AU2019213286A1 (en) * 2018-01-24 2020-07-30 The Council Of The Queensland Institute Of Medical Research HPV immunotherapy
CN112368386A (en) * 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 Consensus antigens
KR20220016137A (en) 2019-05-30 2022-02-08 그릿스톤 바이오, 인코포레이티드 modified adenovirus
CN114901676A (en) * 2019-08-15 2022-08-12 国家生物技术研究所公司 Delivery peptides and methods of use thereof
WO2021247534A2 (en) * 2020-06-01 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
KR20230046313A (en) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 Multi-epitope vaccine cassette
CN117730247A (en) 2021-07-12 2024-03-19 Isa制药有限公司 Improved quantification of substances in complex mixtures
CN113842455B (en) * 2021-08-27 2022-05-13 北京康乐卫士生物技术股份有限公司 Adjuvant of novel coronavirus vaccine, application of adjuvant and novel coronavirus bivalent recombinant vaccine
KR102545000B1 (en) * 2021-10-20 2023-06-16 전옥님 The electromagnetic shielding sheet using graphene
WO2023143445A1 (en) * 2022-01-25 2023-08-03 厦门大学 Epitope peptide and antibody for treating hbv infection and related diseases
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT534618E (en) 1991-08-26 2006-08-31 Scripps Research Inst PEPTIDES FOR INDUCTION OF CITOTOXIC T-LYMPHOCYTE RESPONSES TO HEPATITIS B VIRUS
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
JP3650110B2 (en) 1993-08-02 2005-05-18 ザ スクリップス リサーチ インスティテュート Peptides for inducing a cytotoxic T lymphocyte response against hepatitis B virus
ES2249907T3 (en) 1998-05-23 2006-04-01 Leiden University Medical Center CD40 UNION BODIES AND CTL PEPTIDES FOR TUMOR TREATMENT.
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
FR2794370B1 (en) 1999-06-03 2003-10-17 Biovector Therapeutics POLYEPITOPIC PROTEIN FRAGMENTS, THEIR OBTAINMENT AND THEIR USES IN PARTICULAR IN VACCINATION
DE10059631A1 (en) 2000-12-01 2002-07-18 Medigene Ag T-cell epitopes of the papillomavirus L1 and E7 proteins and their use in diagnostics and therapy
WO2002070006A2 (en) 2000-12-08 2002-09-12 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP2112157B1 (en) * 2000-12-08 2014-07-23 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
FR2824326B1 (en) 2001-05-04 2004-03-19 Commissariat Energie Atomique MIXTURE OF PEPTIDES FROM PAPILLOMAVIRUS E6 AND / OR E7 PROTEINS AND THEIR APPLICATIONS
EP1479761A1 (en) 2003-05-21 2004-11-24 PrimaGen Holding B.V. New enterovirus, vaccines, medicaments and diagnostic kits
SI1687019T1 (en) * 2003-11-20 2018-04-30 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
CA2996732C (en) 2007-03-26 2020-10-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
CN111686244A (en) 2007-05-31 2020-09-22 莱顿教学医院 HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
EP2155240B1 (en) * 2007-05-31 2014-04-30 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Intradermal hpv peptide vaccination
CA2689536A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
KR20090125628A (en) 2008-06-02 2009-12-07 바이오코아 주식회사 Immunogenic peptide and composition for preventing or treating hpv-related diseases
KR20090125629A (en) 2008-06-02 2009-12-07 바이오코아 주식회사 Immunogenic peptide and composition for preventing or treating hpv-related diseases
WO2010132867A1 (en) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
WO2012122535A2 (en) * 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013006050A1 (en) 2011-07-06 2013-01-10 Isa Pharmaceuticals B.V. Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
EP2859011B1 (en) * 2012-06-06 2019-12-11 Bionor Immuno AS Peptides derived from viral proteins for use as immunogens and dosage reactants
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2014168874A2 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
KR102569204B1 (en) 2014-06-02 2023-08-22 아이에스에이 파마슈티컬즈 비.브이. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection

Also Published As

Publication number Publication date
IL263846A (en) 2019-01-31
IL291537A (en) 2022-05-01
US20230233658A1 (en) 2023-07-27
KR20230030032A (en) 2023-03-03
EA201990071A1 (en) 2019-06-28
CN109641039B (en) 2023-08-04
US20200297835A1 (en) 2020-09-24
IL263846B (en) 2022-04-01
JP7115803B2 (en) 2022-08-09
CN117018170A (en) 2023-11-10
MX2023003875A (en) 2023-04-18
AU2017281389B2 (en) 2024-02-22
EP3471758A1 (en) 2019-04-24
US20190231863A1 (en) 2019-08-01
US11426458B2 (en) 2022-08-30
KR20190020098A (en) 2019-02-27
CN109641039A (en) 2019-04-16
JP2019525950A (en) 2019-09-12
IL291537B2 (en) 2023-11-01
IL291537B1 (en) 2023-07-01
WO2017220463A1 (en) 2017-12-28
AU2017281389A1 (en) 2019-02-07
CA3027459A1 (en) 2017-12-28
MY189551A (en) 2022-02-16
JP2022141878A (en) 2022-09-29
MX2018015749A (en) 2019-06-17
ZA202100578B (en) 2023-03-29
US10702598B2 (en) 2020-07-07
EP3552623A1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201811432WA (en) Rna for cancer therapy
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807912SA (en) Vaccine against rsv
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201810561YA (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same